You can now read 10 articles a month for free. Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

Biogen Idec gains on new MS drug’s sales

Biogen targets autoimmune and neurodegenerative disorders and hemophilia.

Suzanne Kreiter/Globe Staff/File

Biogen targets autoimmune and neurodegenerative disorders and hemophilia.

Continue reading below

Biogen Idec Inc. shares climbed 4.9 percent to a record $223.98 before closing at $223.61, up
­4.7­ percent. The Weston company’s new multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis and Sanofi, Bloomberg News reported, suggesting the treatment may beat sales estimates for the year. Total­ prescriptions more than doubled during the third week of the launch to 730 from 332 the previous week, according to Wells Fargo & Co.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week